Two Blades Foundation licenses TAL Code technology to Bayer CropScience
News May 01, 2012
The Two Blades Foundation (2Blades) announced today the completion of a non-exclusive license agreement with Bayer CropScience AG for access to the TAL Code technology for commercial uses in certain crop plants.
The Transcription Activator Like (TAL) effector code enables a number of highly useful tools to target specific loci in a genome and modulate the expression of genes. Named Method of the Year in 2011 by the journal Nature Methods (9:1 doi:10.1038/nmeth.1852), the technology is based on novel sequence-specific DNA-binding proteins that can be designed quickly and easily to recognize virtually any sequence of interest. Application of these tools in plants will facilitate the optimization of beneficial genes and the development of more productive crops in the future.
The license agreement with Bayer CropScience will enable Bayer to pursue their mission of using modern plant breeding techniques to improve the quality of crops and vegetables. Bayer will grant 2Blades access to its improvements to the technology for use in 2Blades’ humanitarian efforts to support subsistence farming. Bayer will also have an option to expand its crop rights in the future. Financial terms of the agreement were not disclosed.
“2Blades is interested in facilitating broad development of the TAL Code technology,” said 2Blades Chief Operating Officer Diana Horvath. “We are pleased that Bayer will deploy this powerful new technology in their crop programs.”
The Two Blades Foundation (www.2blades.org) is a 501(c)3 not-for-profit corporation dedicated to developing durable disease resistance in agricultural crops.
Maize Pest Exploits Plant Defense Compounds to Protect ItselfNews
Rootworm larvae are able to sequester plant defense compounds from maize roots in a non-toxic form and can activate the toxins whenever they need them to protect themselves against their own enemies.READ MORE
XenoGesis Ramps up Growth Plans with Appointment of New Global Head of Business DevelopmentNews
XenoGesis has appointed Dr Rachel Hemsley as global head of business development in a drive to support its ambitious growth plans.READ MORE
Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing GrantNews
€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.READ MORE